Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary
Does the drug Obeticholic Acid help treat patients with primay biliary cholangitis?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
Primary Biliary Cholangitis (PBC) formerly known as primary biliary cirrhosis is a
serious, life-threatening, bile acid related liver disease of unknown cause. Without
treatment, it frequently progresses to liver fibrosis and eventual cirrhosis requiring
liver transplantation or resulting in death. The investigational drug, Obeticholic
Acid (OCA) helps prevent liver damage and improves liver function. The study will
assess the effect of OCA compared to placebo, combined with stable standard care,
on clinical outcomes in PBC patients.
Study Contact InformationStudy Coordinator: Chelsea Vallone
Phone: (585) 275-4763
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search